CAMBRIDGE, Mass., April 28, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will hold its First Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., Eastern Time, on Thursday, May 7, 2015. Merrimack also announced it will present at the Credit Suisse 2015 Antibody Conference on Wednesday, May 6, 2015 at 10:55 a.m., Eastern Time, in New York.
First Quarter 2015 Investor Conference Call
The call will cover an update on Merrimack's progress as well as a summary of first quarter 2015 financials. A press release detailing the information to be discussed on the call will be issued the afternoon of Thursday, May 7. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 34571198.
A listen-only webcast of the call will be available in the Investors section of Merrimack's website, http://investors.merrimackpharma.com, and a replay of the call will be archived there for six weeks.
Credit Suisse 2015 Antibody Conference
Gavin MacBeath, Co-Founder and Head of Translational Research, is scheduled to present at the Credit Suisse 2015 Antibody Conference on Wednesday, May 6, 2015 at 10:55 a.m., Eastern Time, in New York.
A live webcast of the presentation will be available in the Investors section of Merrimack's website, http://investors.merrimackpharma.com, and a replay of the presentation will be archived there for two weeks.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has submitted a New Drug Application for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. For more information, please visit Merrimack's website at www.merrimackpharma.com or connect on Twitter at @MerrimackPharma.
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
Geoffrey Grande, CFA
SOURCE Merrimack Pharmaceuticals, Inc.